Daily Voice: Ashwini Shami of OmniScience says this sector is severely mispriced, offers strong investment opportunity

OmniScience has been overweight on the banking sector, said Ashwini Shami.

Banking is one of the few major sectors that Ashwini Shami, co-founder of OmniScience Capital, finds severely mispriced. “The sector provides an…[Read more]

AARYANA MATASCO has been appointed as the Public Relations partner for Siddha Group’s Mumbai portfolio.

AARYANA MATASCO, the Investor Relations & Public Relations arm of VRIGHT AARYANA HOLDINGS PVT. LTD., will lead strategic communications and media engagement for Siddha Group—one of India’s most trusted real estate developers, known for landm…[Read more]

From BSE’s Floor Frenzy to Digital Disarray: Why We Need a Better Way to Share Market Information

In 1995, trading on the BSE floor was a frenzied, physical affair — filled with shouting, pushing, scribbling, and raw human energy. It was a far cry from the calm, algorithm-driven trading systems we use today.

(View the actual footage — it speak…[Read more]

From Floor Frenzy to Digital Disarray: Why We Need a Better Way to Share Market Information

In 1995, trading on the BSE floor was a frenzied, physical affair — filled with shouting, pushing, scribbling, and raw human energy. It was a far cry from the calm, algorithm-driven trading systems we use today.

(View the actual footage — it speaks vol…[Read more]

IPO and Fundraising Update as of July 18, 2025:

Amber Group
Target Fundraise: ₹3,000 crore

Mode: QIP + Upcoming IPO

Purpose: Expansion in electronics manufacturing

Status: IPO pipeline in progress

Mainboard IPO Pipeline (RHPs Expected Within a Week)
Brigade Hotels
Expected to file RHP soon

GNG Electronics Ltd (Electronics Bazaar)
IPO D…[Read more]

Regulatory actions from SEBI, RBI, and other major global regulators as of July 18, 2025:

India – SEBI
• ETF Valuation Standardization
SEBI has proposed a unified valuation methodology for physical gold and silver held by ETFs. Public comments are invited until August 6, 2025, with implementation planned soon after.

• Venture Capital Funds Settl…[Read more]

Glenmark Pharmaceuticals (Not Rated)

CMP: Rs.2,203 Market Cap: Rs.622 bn

Investor day meet KTA’s

Summary
India business continues to be the largest and fastest growing segment for the company. It will continue to focus on cardiology and anti-diabetes therapies in this market. Current revenue mix is – India 34%, Emerging market 2…[Read more]